LIGAND PHARMACEUTICALS INC

LGND

LIGAND PHARMACEUTICALS INC

LGND

Insider Sentiment (TTM):

Last Purchase:2025-05-09Last Sale:2026-06-16Shares Purchased (TTM):0Shares Sold (TTM):87,237

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:20,321,160Shares Outstanding:19,883,000Institutional Ownership Pct.:102.20%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	1,007	115	175	139	68	48	72	64	18	50	23	19
Short Term Investments	351	664	559	525	177	161	184	156	209	261	147	171
Accounts Receivable Net Current	67	53	60	58	41	38	38	34	37	28	33	36
Inventory Net	10	13	9	12	15	15	14	17	19	21	24	25
Income Taxes Receivable	3	1	1	1	1	4	4	8	0	0	6	0
Derivative Assets Current	-	-	-	-	-	-	-	11	20	-	-	-
Prepaid Expense Current	-	-	-	-	-	-	2	-	2	1	1	-
Other Assets Current	6	6	6	7	5	13	9	20	7	7	3	2
Assets Held For Sale Not Part Of Disposal Group Cu…	-	-	-	-	35	30	-	-	-	-	-	-
Assets Current	1,457	865	832	754	353	309	332	309	312	369	237	254
Intangible Assets Net Excluding Goodwill	209	217	225	234	250	258	267	275	283	291	300	315
Goodwill	102	102	102	102	102	102	105	105	105	105	103	104
Derivative Assets Noncurrent	18	14	16	9	18	18	11	19	35	-	4	-
Property Plant And Equipment Net	-	3	4	3	4	4	15	15	15	15	16	16
Equity Method Investments	42	32	47	42	-	-	0	1	2	10	13	14
Equity Securities F V N I Noncurrent	-	-	-	-	-	-	-	-	-	-	-	33
Operating Lease Right Of Use Asset	-	7	5	8	8	7	7	7	7	6	6	6
Other Investments	114	88	121	107	11	11	11	12	11	37	37	-
Deferred Income Tax Assets Net	37	8	8	10	1	1	0	0	0	0	0	9
Finance Lease Right Of Use Asset	-	-	-	-	-	-	3	3	3	3	3	4
Other Assets Noncurrent	12	13	13	3	9	8	32	8	12	11	6	8
Assets	2,186	1,532	1,561	1,477	949	905	942	955	866	914	787	769
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	9	5	3	4	9	5	5	5	2	2	2	2
Accrued Liabilities Current	32	32	31	24	17	24	28	16	12	12	12	11
Taxes Payable Current	3	2	1	1	0	2	1	2	2	1	-	1
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	0	0
Convertible Debt Current	-	-	-	-	-	-	-	-	-	-	0	0
Finance Lease Liability Current	-	-	-	-	0	0	0	0	0	0	0	-
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	-	-	1	-
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	36	26	-	-	-	-	-	-
Other Liabilities Current	1	0	0	0	-	-	1	-	-	-	-	1
Contract With Customer Liability Current	-	-	1	-	0	0	1	1	1	1	1	-
Liabilities Current	47	41	37	31	65	59	37	25	19	18	17	16
Deferred Income Noncurrent	-	-	0	0	0	0	2	3	3	3	1	-
Operating Lease Liability Noncurrent	4	4	4	4	5	4	6	6	6	5	6	6
Senior Long Term Notes	1,127	447	446	445	-	-	0	-	-	-	-	-
Deferred Income Tax Liabilities Net	22	23	36	23	32	29	33	46	30	51	32	33
Other Liabilities Noncurrent	17	17	17	20	14	14	30	30	29	28	28	44
Liabilities	1,218	535	543	527	120	110	111	114	91	107	86	101
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	380	397	401	363	359	341	337	309	239	218	199	184
Accumulated Other Comprehensive Income Loss Net Of…	4	5	8	9	8	-2	-6	2	-1	-1	-1	-1
Retained Earnings Accumulated Deficit	583	595	608	578	461	457	499	530	537	589	503	485
Stockholders Equity	968	997	1,017	950	827	796	830	841	775	807	701	668
Liabilities And Stockholders Equity	2,186	1,532	1,561	1,477	949	905	942	955	866	914	787	769
Common Stock Shares Issued	20	20	20	20	19	19	19	19	18	18	18	17
Shares Outstanding	20	20	20	20	19	19	19	19	18	18	18	17
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	60	60	60	60	60	60	60	60	60	60	60	60

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	4.76%	37.12%	35.73%	-	-	-	-	-	-	-	-	-
2025	-2.19%	9.26%	30.01%	7.76%	13.10%	24.60%	0.35%	-3.28%	-0.66%	3.28%	16.90%	7.51%
2024	5.84%	4.85%	33.33%	13.37%	4.34%	19.82%	0.18%	-9.95%	-5.13%	-11.52%	-14.12%	-14.47%
2023	-	-	-	-5.91%	-15.27%	-29.91%	7.52%	30.71%	39.92%	-10.52%	-8.67%	8.46%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	31.18	21.28	22.23	24.69	5.45	5.27	8.93	12.49	16.82	20.70	14.15	16.15
Quick Ratio	30.96	20.95	21.98	24.30	5.21	5.02	8.50	11.81	15.71	19.44	12.65	14.54
Working Capital	1.41B	824.75M	794.82M	723.38M	288.21M	250.63M	294.45M	284.62M	293.69M	351.10M	220.65M	238.27M
Leverage & Debt
Debt to Equity	1.26	0.54	0.53	0.55	0.15	0.14	0.13	0.14	0.12	0.13	0.12	0.15
Interest Coverage TTM	15.30	16.91	8.70	4.59	-9.39	-16.43	-7.44	-7.16	-10.64	1.30	18.20	-6.27
Debt Ratio	0.56	0.35	0.35	0.36	0.13	0.12	0.12	0.12	0.11	0.12	0.11	0.13
Efficiency & Turnover
Asset Turnover TTM	0.19	0.23	0.21	0.21	0.21	0.20	0.19	0.18	0.16	0.14	0.17	0.17
Days Sales Outstanding TTM	68.03	61.09	66.70	66.74	76.63	67.30	77.85	84.20	89.52	88.88	88.03	120.21
Receivables Turnover TTM	5.37	5.97	5.47	5.47	4.76	5.42	4.69	4.34	4.08	4.11	4.15	3.04
Per Share Metrics
Diluted EPS TTM	9.03	7.72	6.13	2.35	-3.81	-6.91	-0.22	2.46	2.34	5.32	2.94	0.95
Free Cash Flow Per Share TTM	6.55	6.19	2.53	1.57	2.77	2.65	5.21	4.08	2.57	1.87	2.66	5.16
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	100.47%	100.50%	100.50%
Operating Profit Margin TTM	32.61%	34.46%	15.29%	6.97%	-18.27%	-34.06%	-13.53%	-10.71%	-12.28%	0.61%	9.09%	-3.12%
Net Profit Margin TTM	67.88%	55.95%	46.42%	19.34%	-40.44%	-73.07%	-2.41%	29.68%	31.57%	81.43%	39.72%	10.73%
Growth Metrics
Net Revenue Growth (1Y)	54.89%	51.24%	60.40%	64.83%	40.54%	53.40%	27.28%	-0.76%	-25.82%	-41.92%	-33.09%	-15.95%
Net Income Growth (1Y)	-359.97%	-215.79%	-3,186.63%	7.38%	-280.02%	-237.65%	-107.73%	174.52%	55.18%	301.89%	-256.33%	-177.40%
EPS Growth (1Y)	-350.43%	-211.76%	-3,019.36%	1.02%	-267.92%	-227.19%	-107.31%	159.04%	48.70%	286.72%	-252.45%	-175.21%
Valuation Metrics
P/E TTM	32.16	25.85	29.38	71.39	-28.96	-15.21	-486.05	40.75	36.04	13.45	23.69	63.19
P/B TTM	6.55	3.98	3.59	3.65	2.66	2.54	2.36	2.19	1.96	1.61	1.76	1.56
P/S TTM	21.83	14.46	13.64	13.80	11.71	11.12	11.73	12.10	11.38	10.96	9.41	6.78
Market Cap	6.34B	3.97B	3.66B	3.47B	2.20B	2.02B	1.96B	1.84B	1.52B	1.30B	1.24B	1.04B
Enterprise Value	5.34B	3.85B	3.48B	3.33B	2.13B	1.97B	1.89B	1.78B	1.50B	1.25B	1.21B	1.02B
Calculated Values
Free Cash Flow TTM	131.44M	123.03M	48.91M	30.76M	53.62M	50.94M	95.23M	75.12M	46.34M	33.15M	46.06M	89.75M
Net Debt	-1.01B	-115.09M	-174.93M	-139.38M	-67.65M	-47.97M	-72.28M	-63.60M	-18.13M	-50.09M	-22.95M	-19.86M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-16Sale

Owner: Sabba, Stephen L

Title: -

Shares: 2,145

Price/Share: $254.00

Value: $544,830.00

Shares Owned: 33,629

Relationship: Director

Ownership: Direct

2026-06-12Sale

Owner: Haas, Jason

Title: -

Shares: 6,461

Price/Share: $255.54

Value: $1,651,043.94

Shares Owned: 4,981

Relationship: Director

Ownership: Direct

2026-06-11Sale

Owner: Aryeh, Jason

Title: -

Shares: 4,500

Price/Share: $250.00

Value: $1,125,000.00

Shares Owned: 102,580

Relationship: Director

Ownership: Direct

2026-06-10Sale

Owner: Lamattina, John L

Title: -

Shares: 4,591

Price/Share: $249.12

Value: $1,143,709.92

Shares Owned: 26,969

Relationship: Director

Ownership: Direct

2026-06-01Sale

Owner: Reardon, Andrew

Title: CLO & Secretary

Shares: 5,000

Price/Share: $227.19

Value: $1,135,950.00

Shares Owned: 41,382

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-16	Sabba, Stephen L	Director	-	Direct	Sale	2,145	254.00	$544,830.00	33,629	4
2026-06-12	Haas, Jason	Director	-	Direct	Sale	6,461	255.54	$1,651,043.94	4,981	4
2026-06-11	Aryeh, Jason	Director	-	Direct	Sale	4,500	250.00	$1,125,000.00	102,580	4
2026-06-10	Lamattina, John L	Director	-	Direct	Sale	4,591	249.12	$1,143,709.92	26,969	4
2026-06-01	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	5,000	227.19	$1,135,950.00	41,382	4
2026-05-13	Kozarich, John W	Director	-	Direct	Sale	1,575	223.50	$352,012.50	41,786	4
2026-05-01	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	5,000	230.82	$1,154,100.00	41,382	4
2026-04-01	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	5,000	201.52	$1,007,600.00	41,382	4
2026-04-01	Kozarich, John W	Director	-	Direct	Sale	467	202.16	$94,408.72	42,253	4
2026-03-23	Sabba, Stephen L	Director	-	Direct	Sale	1,000	207.87	$207,870.00	32,793	4
2026-03-11	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	3,057	225.00	$687,825.00	21,010	4
2026-03-06	Lamattina, John L	Director	-	Direct	Sale	2,161	200.76	$433,842.36	30,724	4
2026-03-04	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	5,000	203.52	$1,017,600.00	36,869	4
2026-03-04	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	13,423	203.83	$2,736,010.09	21,662	4
2026-03-03	Sabba, Stephen L	Director	-	Direct	Sale	2,034	201.50	$409,851.00	33,793	4
2026-03-02	Kozarich, John W	Director	-	Direct	Sale	467	200.83	$93,787.61	42,720	4
2026-02-02	Kozarich, John W	Director	-	Direct	Sale	467	194.47	$90,817.49	43,187	4
2026-01-02	Kozarich, John W	Director	-	Direct	Sale	467	189.23	$88,370.41	43,654	4
2025-12-12	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	1,804	188.31	$339,711.24	26,186	4
2025-12-01	Kozarich, John W	Director	-	Direct	Sale	467	196.82	$91,914.94	44,121	4
2025-11-07	Gray, Nancy Ryan	Director	-	Direct	Sale	6,571	205.45	$1,350,011.95	8,094	4
2025-11-07	Lamattina, John L	Director	-	Direct	Sale	4,179	205.45	$858,575.55	30,724	4
2025-11-03	Kozarich, John W	Director	-	Direct	Sale	467	190.72	$89,066.24	44,588	4
2025-10-01	Kozarich, John W	Director	-	Direct	Sale	467	179.30	$83,733.10	45,055	4
2025-09-23	Aryeh, Jason	Director	-	Direct	Sale	10,000	171.10	$1,711,000.00	69,289	4
2025-09-02	Kozarich, John W	Director	-	Direct	Sale	467	162.76	$76,008.92	45,522	4
2025-08-01	Kozarich, John W	Director	-	Direct	Sale	467	131.88	$61,587.96	45,989	4
2025-07-10	Kozarich, John W	Director	-	Direct	Sale	934	125.00	$116,750.00	46,456	4
2025-06-23	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	500	114.08	$57,040.00	31,903	4
2025-06-10	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	500	114.54	$57,270.00	32,403	4
2025-05-15	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	1,000	104.00	$104,000.00	32,903	4
2025-05-09	Davis, Todd C	Director,Officer	Chief Executive Officer	Direct	Purchase	9,510	104.92	$997,789.20	161,234	4
2025-05-09	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Purchase	1,500	104.15	$156,225.00	27,932	4
2025-03-04	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	5,000	115.03	$575,150.00	18,879	4
2024-12-23	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	2,104	116.37	$244,842.48	20,647	4
2024-11-27	Lamattina, John L	Director	-	Direct	Sale	2,406	123.65	$297,501.90	29,515	4
2024-09-23	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	2,000	99.60	$199,200.00	22,534	4
2024-09-23	Korenberg, Matthew E	Officer	President & COO	Direct	Sale	9,772	101.24	$989,317.28	50,777	4
2024-09-20	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	1,275	103.93	$132,510.75	24,610	4
2024-08-28	Reardon, Andrew	Officer	CLO & Secretary	Direct	Sale	1,500	106.39	$159,585.00	22,534	4
2024-08-26	Korenberg, Matthew E	Officer	President & COO	Direct	Sale	11,389	105.67	$1,203,475.63	49,510	4
2024-08-09	Korenberg, Matthew E	Officer	President & COO	Direct	Sale	18,245	98.50	$1,797,132.50	68,368	4
2024-08-08	Davis, Todd C	Director,Officer	Chief Executive Officer	Direct	Purchase	2,500	97.39	$243,475.00	123,010	4
2024-05-17	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	5,156	86.66	$446,818.96	23,379	4
2024-05-14	Korenberg, Matthew E	Officer	President & Chief Operating	Direct	Sale	14,158	85.38	$1,208,810.04	86,263	4
2024-05-09	Gray, Nancy Ryan	Director	-	Direct	Sale	934	83.20	$77,708.80	5,633	4
2024-05-09	Reardon, Andrew	Officer	Chief Legal Officer &	Direct	Sale	10,000	83.04	$830,400.00	22,205	4
2024-03-05	Sabba, Stephen L	Director	-	Direct	Sale	1,893	74.30	$140,649.90	28,926	4
2024-02-28	Espinoza, Octavio	Officer	Chief Financial Officer	Direct	Sale	140	88.46	$12,384.40	29,755	4
2023-09-22	Davis, Todd C	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	4,000	59.38	$237,520.00	73,090	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.20%

Inst. Shares: 20,321,160

Shares Outstanding: 19,883,000

2025-12-31

105.48%

Inst. Shares: 20,398,548

Shares Outstanding: 19,338,000

2025-09-30

103.74%

Inst. Shares: 20,309,390

Shares Outstanding: 19,578,000

2025-06-30

97.56%

Inst. Shares: 18,854,984

Shares Outstanding: 19,327,000

2025-03-31

93.45%

Inst. Shares: 17,934,199

Shares Outstanding: 19,191,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	20,321,160	19,883,000	102.20%
2025-12-31	20,398,548	19,338,000	105.48%
2025-09-30	20,309,390	19,578,000	103.74%
2025-06-30	18,854,984	19,327,000	97.56%
2025-03-31	17,934,199	19,191,000	93.45%
2024-12-31	17,392,076	18,290,000	95.09%
2024-09-30	17,260,878	18,419,000	93.71%
2024-06-30	16,491,929	18,028,000	91.48%
2024-03-31	15,901,649	17,732,000	89.68%
2023-12-31	15,681,141	17,298,000	90.65%
2023-09-30	15,153,950	17,380,000	87.19%
2023-06-30	14,983,043	17,276,000	86.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

LIGAND PHARMACEUTICALS INC (LGND) — SEC Financial Statements & Analysis

LIGAND PHARMACEUTICALS INC (LGND) is a pharmaceutical preparations company, incorporated in DE. LIGAND PHARMACEUTICALS INC trades on Nasdaq, OTC as: LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), LIGAND PHARMACEUTICALS INC reported a 54.89% year-over-year revenue growth, a Gross Profit Margin of 100.47% (TTM), a Debt-to-Equity ratio of 1.26x, a Price-to-Sales (P/S) ratio of 21.83x (TTM), a Price-to-Book (P/B) ratio of 6.55x (TTM), at a market cap of $6.34B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 54.89%
Gross Profit Margin TTM: 100.47%
Debt To Equity: 1.26x
P/S TTM: 21.83x
P/B TTM: 6.55x
Market Cap: $6.34B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is LIGAND PHARMACEUTICALS INC in?

LIGAND PHARMACEUTICALS INC (LGND) operates in the Pharmaceutical Preparations industry.

What is LGND's market cap?

LIGAND PHARMACEUTICALS INC (LGND) has a market capitalization of $6.34B as of 2026-06-30.

What is LGND's P/E ratio?

LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month P/E ratio is 32.16x as of 2026-06-30.

What exchange does LGND trade on?

LIGAND PHARMACEUTICALS INC (LGND) trades on the Nasdaq, OTC.

Where is LIGAND PHARMACEUTICALS INC incorporated?

LIGAND PHARMACEUTICALS INC is incorporated in DE.